Accueil・Liste d'Actions・Geron Corp

Geron Corp

Ouvert

SecteurSoins de santé

1.56 17.29

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.34

Max

1.6099999999999999

Chiffres clés
By Trading Economics
Revenu	25M -3.6M
Ventes	3.8M 52M
BPA	-0.005
Marge bénéficiaire	-7.026
Employés	258
EBITDA	27M 3.8M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+198.51% upside

Dividendes
By Acuity
Prochains Résultats	5 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-185M 821M
Ouverture précédente	-15.73
Clôture précédente	1.56

Sentiment de l'Actualité

By Acuity

20%

80%

55 / 340 Classement par Healthcare

Geron Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 août 2026, 23:36 UTC

Geron Corp shares are lower in after-market trading, nearing the bottom of their one-month range and below the 20-day moving average.

3 août 2026, 23:06 UTC

Geron Corp shares are lower in after-market hours, continuing a steady decline since Monday's close and remaining below the 20-day moving average.

31 juil. 2026, 20:02 UTC

Geron Corp shares are lower as the Biotechnology sub-sector declines. The stock pulled back from an earlier session high, finishing below its 20-day moving average.

30 juil. 2026, 20:56 UTC

Geron Corp shares are higher in after-market hours, influenced by positive corporate earnings amid broader market uncertainty following the Federal Reserve's interest rate decision.

29 juil. 2026, 19:32 UTC

Macro Event

Geron Corp shares are lower as market volatility rises following the Federal Reserve's interest rate decision amid ongoing economic growth and inflation concerns.

28 juil. 2026, 18:51 UTC

Shares of Geron Corp are lower today amid broader market volatility and uncertainty regarding Federal Reserve decisions. The stock declined since Monday's close.

27 juil. 2026, 23:16 UTC

Geron Corp shares are lower in after-market trading, despite earlier gains, with no specific company news driving the decline.

24 juil. 2026, 19:46 UTC

Geron Corp shares are lower in Friday's session amid broader market volatility and uncertainty from fluctuating oil prices and new U.S. tariffs.

23 juil. 2026, 10:11 UTC

Shares of Geron Corp are higher in pre-market hours, trading above their 20-day moving average. No specific company news was identified.

22 juil. 2026, 18:51 UTC

Geron Corp shares are lower today amid broader market trends, as crude oil prices surge due to geopolitical tensions.

21 juil. 2026, 23:41 UTC

Geron Corp shares are lower in after-market trading, declining to their lowest point since Tuesday's close. No specific news was identified to explain the drop.

20 juil. 2026, 23:56 UTC

Geron Corp shares are lower in after-market hours, continuing a decline since Monday's close amid broader market uncertainties and a drop in the leading economic index.

Comparaison

Variation de prix

Geron Corp prévision

Objectif de Prix

By TipRanks

198.51% hausse

Prévisions sur 12 Mois

Moyen 4 USD 198.51%

Haut 5 USD

Bas 3 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

55 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Geron Corp

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.